Hasil Pencarian - C.M. Montecucco

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    MonitorNet: studio italiano osservazionale multicentrico per la valutazione del profilo rischio-beneficio dei farmaci biologici nella pratica clinica reumatologica

    MonitorNet: studio italiano osservazionale multicentrico per la valutazione del profilo rischio-beneficio dei farmaci biologici nella pratica clinica reumatologica oleh S. Bombardieri, C.M. Montecucco, F. Salaffi, P. Sfriso, S. Todesco

    Diterbitkan 2011-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Socio-demographic aspects and therapeutic pathways in patients with rheumatoid arthritis in Italy

    Socio-demographic aspects and therapeutic pathways in patients with rheumatoid arthritis in Italy oleh C.M. Montecucco, L. Pardini, T. Manacorda, C.M. Vaccaro, F. Salaffi

    Diterbitkan 2011-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    The risk/benefit profile of biologic drugs in real-world rheumatology practice. From ANTARES to MonitorNet

    The risk/benefit profile of biologic drugs in real-world rheumatology practice. From ANTARES to MonitorNet oleh C.M. Montecucco, B. Canesi, S. Bombardieri, F. Salaffi, P. Sfriso, S. Todesco

    Diterbitkan 2011-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Systematic review of 2008-2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis

    Systematic review of 2008-2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis oleh M. Todoerti, W. Maglione, E. Bernero, A. Bortoluzzi, M. Colaci, E. Galuppi, S. Paolino, R. Talarico, M. Cutolo, C. Ferri, F. Trotta, S. Bombardieri, C.M. Montecucco, L. Sinigaglia

    Diterbitkan 2013-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: